Physician profile
Azmey A Matarieh
NPI 1083718423
$762,406.85
in general payments reported to CMS, 2019-2025
35 companies · $104K in 2025
The $104K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $48K · 2021: $98K · 2022: $163K · 2023: $110K · 2024: $105K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $280K · Travel and Lodging: $22K · Food and Beverage: $11K · Consulting Fee: $6,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,868.81 |
| Travel and Lodging | $21,780.26 |
| Food and Beverage | $11,399.30 |
| Consulting Fee | $6,310.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302,151.35 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $195,053.78 | 2019-2024 | Xarelto, Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138,084.88 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $71,599.27 | 2019-2025 | Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $25,115.59 | 2019-2025 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $18,925.53 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $2,000.00 | 2020 | |
| Abbott Laboratories | $1,929.56 | 2019-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $1,854.31 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $1,287.39 | 2019-2025 | Watchman Access System, Farapulse, Watchman |
| Abiomed | $865.97 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $514.76 | 2022-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $501.05 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $349.81 | 2022-2023 | Optimizer |
| Itamar Medical INC | $345.08 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $255.02 | 2021-2025 | Corevalve Evolut R |
| Heartflow, INC. | $215.95 | 2024-2025 | |
| Biotronik INC. | $158.14 | 2021-2022 | |
| Angiodynamics, INC. | $141.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.81 | 2021-2025 | Lifevest |
| Zoll Respicardia, INC. | $115.21 | 2021 | |
| Shockwave Medical, INC | $101.27 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Endotronix, INC. | $99.25 | 2023 | Cordella Pulomonary Artery Pressure Sensor |
| Esperion Therapeutics, INC. | $91.64 | 2025 | Nexletol |
| Livanova USA, INC. | $89.86 | 2019 | |
| Pfizer INC. | $82.78 | 2019-2025 | |
| Cvrx, INC. | $71.44 | 2024-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $59.68 | 2023-2024 | Uptravi, Opsumit |
| Smith+Nephew, INC. | $52.93 | 2023 | Grafix Pl |
| Stryker Corporation | $45.90 | 2025 | |
| Cardiva Medical, INC. | $40.50 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Sanofi-Aventis U.S. LLC | $24.37 | 2019 | |
| Teleflex LLC | $23.09 | 2023 | Manta |
| Kestra Medical Technology Services, INC. | $15.49 | 2023 | Assure Wcd |
| Scpharmaceuticals INC. | $15.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azmey Matarieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.